[IO Summit 2022] Ready-to-Use Cell-Based Assays to Enable Immunotherapy Drug Development for Checkpoint Receptors
- File Name/Number:
- IO Summit
Regulation of immune responses is tightly controlled through a balance of co-stimulatory and inhibitory checkpoint receptors, often exploited by many cancers. Therefore, therapeutics that block inhibitory receptors or activate immuno-stimulatory checkpoint receptors have proved to be powerful agents to restore anti-tumor immune responses.